Previous 10 | Next 10 |
ANN ARBOR, Mich., July 27, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer of Esperion will participate in the upcoming BTIG Virtual Biotechnology Conference. Live audio webcasts of these events can be access...
ANN ARBOR, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021. Following the release, company management will host a webcast and...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The short-squeeze rally in meme stocks like GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) is poised to go down in financial history books in terms of shareholder gains. However, a short squeeze is onl...
Thanumporn Thongkongkaew/iStock via Getty Images S3 Partners updates on the U.S. stocks with the highest percentage of short interest as the calendar turns to the second half of the year. While the average short interest as a percentage of total float for a U.S. stock is 5.39%, the list of na...
Esperion Therapeutics (ESPR) announces the appointment of JoAnne Foody as the company's chief medical officer, effective immediately.Foody brings more than 20 years of experience in academic and preventive cardiology to Esperion.She joins ESPERION after six years with John...
ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately. She will serve as a member of the executive team and report to Sheldon Koenig, President and C...
Esperion Therapeutics (ESPR) announces the appointment of Sheldon Koenig as the company's president and chief executive officer, effective immediately.Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space, the company...
-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior ...
- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p<0.0001) - - Patients considere...
Esperion recently reported their Q1 earnings that revealed a big miss on EPS and revenue. Consequently, the share price got cut ~30% as Street analyst cut their targets. Despite having impressive clinical data, NEXLETOL and NEXLIZET have had a disappointing launch thus far. However, t...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...